186 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
to a provision for the reverse-payment antitrust litigation over certain HIV medicines, as well as $36 million attributable to an update to the estimated … million related to a provision for the reverse-payment antitrust litigation over certain HIV medicines, as well as $36 million attributable to an update
8-K
EX-99.1
vfpsd3hnczi
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
5pfpon7k6y0
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
l67g56ed
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-5.3
ltl3fp1nhryah3w
10 Nov 21
Entry into a Material Definitive Agreement
4:31pm
S-3ASR
EX-5.3
6x30c
27 Oct 21
Automatic shelf registration
7:42am